相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the gardos channel blocker senicapoc (ICA-17043)
Kenneth I. Ataga et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Amyloid-β Protein Oligomer at Low Nanomolar Concentrations Activates Microglia and Induces Microglial Neurotoxicity
Izumi Maezawa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
The Beneficial Effect of Blocking Kv1.3 in the Psoriasiform SCID Mouse Model
Amos Gilhar et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2011)
Type 1 Diabetes: Etiology, Immunology, and Therapeutic Strategies
Tom L. Van Belle et al.
PHYSIOLOGICAL REVIEWS (2011)
KCNN4 Gene Variant Is Associated With Ileal Crohn's Disease in the Australian and New Zealand Population
Lisa A. Simms et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Immunomodulatory drug treatment in multiple sclerosis
Rina Aharoni
EXPERT REVIEW OF NEUROTHERAPEUTICS (2010)
New pathophysiological insights and modern treatment of IBD
Matthias A. Engel et al.
JOURNAL OF GASTROENTEROLOGY (2010)
Ulcerative Colitis and Cancer
Mahmoud N. Kulaylat et al.
JOURNAL OF SURGICAL ONCOLOGY (2010)
Inhibition of the K+ channel KCa3.1 ameliorates T cell-mediated colitis
Lie Di et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Therapeutic potential of KCa3.1 blockers: recent advances and promising trends
Heike Wulff et al.
Expert Review of Clinical Pharmacology (2010)
Voltage-gated potassium channel Kv1.3 blocker as a potential treatment for rat anti-glomerular basement membrane glomerulonephritis
Toshitake Hyodo et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2010)
The K+ channels KCa3.1 and Kv1.3 as novel targets for asthma therapy
Peter Bradding et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Endothelial Ca2+-activated K+ channels in normal and impaired EDHF-dilator responses - relevance to cardiovascular pathologies and drug discovery
Ivica Grgic et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia
Kenneth I. Ataga et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
The functional network of ion channels in T lymphocytes
Michael D. Cahalan et al.
IMMUNOLOGICAL REVIEWS (2009)
Engineering a Stable and Selective Peptide Blocker of the Kv1.3 Channel in T Lymphocytes
M. W. Pennington et al.
MOLECULAR PHARMACOLOGY (2009)
Voltage-gated potassium channels as therapeutic targets
Heike Wulff et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Mechanisms of Disease: Psoriasis.
Frank O. Nestle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels
Anthony J. Harmar et al.
NUCLEIC ACIDS RESEARCH (2009)
Disruption of the Gardos channel (KCa3.1) in mice causes subtle erythrocyte macrocytosis and progressive splenomegaly
Ivica Grgic et al.
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY (2009)
Renal fibrosis is attenuated by targeted disruption of KCa3.1 potassium channels
Ivica Grgic et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Local delivery of the K(Ca)3.1 blocker, TRAM-34, prevents acute angioplasty-induced coronary smooth muscle phenotypic modulation and limits stenosis
D. L. Tharp et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2008)
KCa3.1: target and marker for cancer, autoimmune disorder and vascular inflammation?
Chuan-Chu Chou et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2008)
Imaging of Effector Memory T Cells during a Delayed-Type Hypersensitivity Reaction and Suppression by Kv1.3 Channel Block
Melanie P. Matheu et al.
IMMUNITY (2008)
The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans
Kazuyoshi Toyama et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Blunted IgE-mediated activation of mast cells in mice lacking the Ca2+-activated K+ channel KCa3.1
Ekaterina Shumilina et al.
JOURNAL OF IMMUNOLOGY (2008)
Clofazimine Inhibits Human Kv1.3 Potassium Channel by Perturbing Calcium Oscillation in T Lymphocytes
Yunzhao R. Ren et al.
PLOS ONE (2008)
KCa3.1 Ca2+-Activated K+ channels regulate human airway smooth muscle proliferation
Malcolm C. Shepherd et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2007)
Pharmacokinetics, toxicity, and functional studies of the selective kv1.3 channel blocker 5-(4-Phenoxybutoxy)Psoralen in rhesus Macaques
L. E. Pereira et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2007)
Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis
Philippe Azam et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2007)
The immunopathology of multiple sclerosis:: An overview
Hans Lassmann et al.
BRAIN PATHOLOGY (2007)
The Ca2+-activated K+ channel KCNN4/KCa3.1 contributes to microglia activation and nitric oxide-dependent neurodegeneration
Vikas Kaushal et al.
JOURNAL OF NEUROSCIENCE (2007)
Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications
Heike Wulff et al.
CURRENT MEDICINAL CHEMISTRY (2007)
Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases
Christine Beeton et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Dose-escalation study of ICA-17043 in patients with sickle cell disease
Kenneth I. Ataga et al.
PHARMACOTHERAPY (2006)
Functional KCa3.1 K+ channels are required for human lung mast cell migration
G. Cruse et al.
THORAX (2006)
Impaired endothelium-derived hyperpolarizing factor-mediated dilations and increased blood pressure in mice deficient of the intermediate-conductance Ca2+-activated K+ channel
Han Si et al.
CIRCULATION RESEARCH (2006)
A new class of blockers of the voltage-gated potassium channel Kv1.3 via modification of the 4- or 7-position of khellinone
AJ Harvey et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases
A Schmitz et al.
MOLECULAR PHARMACOLOGY (2005)
The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain
H Rus et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Blocking ion channel KCNN4 alleviates the symptoms of experimental autoimmune encephalomyelitis in mice
EP Reich et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2005)
Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases
C Beeton et al.
MOLECULAR PHARMACOLOGY (2005)
K+ channel types targeted by synthetic OSK1, a toxin from Orthochirus scrobiculosus scorpion venom
S Mouhat et al.
BIOCHEMICAL JOURNAL (2005)
Expression of CCR7 in multiple sclerosis:: Implications for CNS immunity
P Kivisäkk et al.
ANNALS OF NEUROLOGY (2004)
K+ channels as targets for specific immunomodulation
KG Chandy et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2004)
Khellinone derivatives as blockers of the voltage-gated potassium channel Kv1.3:: Synthesis and immunosuppressive activity
JB Baell et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Functional importance of Ca2+-activated K+ channels for lysophosphatidic acid-induced microglial migration
T Schilling et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2004)
Kv1.3 channel gene-targeted deletion produces super-smeller mice with altered glomeruli, interacting scaffolding proteins, and biophysics
DA Fadool et al.
NEURON (2004)
K+ channel expression during B cell differentiation:: Implications for immunomodulation and autoimmunity
H Wulff et al.
JOURNAL OF IMMUNOLOGY (2004)
Immunopathogenic mechanisms in psoriasis
JE Gudjonsson et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2004)
The K+ channel iKCA1 potentiates Ca2+ influx and degranulation in human lung mast cells
SM Duffy et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2004)
Physiological roles of the intermediate conductance, Ca2+-activated potassium channel Kcnn4
T Begenisich et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Extracellular ATP induces oscillations of intracellular Ca2+ and membrane potential and promotes transcription of IL-6 in macrophages
PJ Hanley et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Selective intermediate-/small-conductance calcium-activated potassium channel (KCNN4) blockers are potent and effective therapeutics in experimental brain oedema and traumatic brain injury caused by acute subdural haematoma
F Mauler et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2004)
Differential voltage-dependent K+ channel responses during proliferation and activation in macrophages
R Vicente et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Kv1.3 potassium channels in human alveolar macrophages
AB Mackenzie et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2003)
Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis
R Köhler et al.
CIRCULATION (2003)
Benzamide derivatives as blockers of Kv1.3 ion channel
SW Miao et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2003)
CCR4 versus CCR10 in human cutaneous TH lymphocyte trafficking
D Soler et al.
BLOOD (2003)
Maurotoxin:: A potent inhibitor of intermediate conductance Ca2+-activated potassium channels
NA Castle et al.
MOLECULAR PHARMACOLOGY (2003)
Identification of a new class of inhibitors of the voltage-gated potassium channel, Kv1.3, with immunosuppressant properties
WA Schmalhofer et al.
BIOCHEMISTRY (2002)
Regulation of Kv1 subunit expression in oligodendrocyte progenitor cells and their role in G1/S phase progression of the cell cycle
R Chittajallu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Cytokine-driven proliferation and differentiation of human naive, central memory, and effector memory CD4+ T cells
J Geginat et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
Selective blockade of T lymphocyte K+ channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis
C Beeton et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Resting and activation-dependent ion channels in human mast cells
SM Duffy et al.
JOURNAL OF IMMUNOLOGY (2001)
Selective blocking of voltage-gated K+ channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation
C Beeton et al.
JOURNAL OF IMMUNOLOGY (2001)
Up-regulation of the IKCa1 potassium channel during T-cell activation -: Molecular mechanism and functional consequences
S Ghanshani et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Design of a potent and selective inhibitor of the intermediate-conductance Ca2+-activated K+ channel, IKCa1:: A potential immunosuppressant
H Wulff et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Ras/MEK/ERK up-regulation of the fibroblast KCa channel FIK is a common mechanism for basic fibroblast growth factor and transforming growth factor-β suppression of myogenesis
TL Peña et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Structure-guided transformation of charybdotoxin yields an analog that selectively targets Ca2+-activated over voltage-gated K+ channels
H Rauer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
分享论文
